An Evolving Story

Corporate Milestones

Our company began in May 2002, when a group of scientists and clinicians in the fields of endocrinology and growth hormone research came together around a shared vision: to leverage four decades of collective knowledge into new therapeutic treatments for endocrine and metabolic disorders.
2002
Tercica U.S. operations established by John A. Scarlett, M.D. and Ross G. Clark, Ph.D.
2003
Tercica raises $44 million in financing
Tercica files for Initial Public Offering
See all 2003 press releases
2004
Tercica becomes a Public Company
Tercica joins Russell 3000® Index
Tercica initiates Phase IIIb clinical trial of short stature caused by primary IGF-1 deficiency
See all 2004 press releases
2005
Tercica secures $75 million committed equity financing facility
Tercica submits marketing authorization application for Increlex in the European Union
FDA Approves Tercica's Increlex for Short Stature Caused by
Severe Primary IGF-1 Deficiency

See all 2005 press releases
2006
Tercica provides Increlex launch and safety updates
Ipsen and Tercica complete worldwide strategic agreement in endocrinology
See all 2006 press releases
2007
Tercica receives marketing approval for Increlex in the European Union
Tercica announces agreement with Genentech for worldwide growth hormone and IGF-1 combination product development and commercializations
Somatuline Depot receives FDA marketing approval for the treatment of acromegaly
See all 2007 press releases
2008
Tercica initiates Phase II clinical trial with next-generation growth hormone product for the treatment of short stature
See all 2008 press releases